Your Article Summary
See Latest ArticlesAfinitor and Sandostatin LAR Phase II data show advanced pancreatic NET patients remain progression-free for nearly 17 months
Novartis, 06/25/09
New data demonstrate that treatment with Afinitor Tablets in combination with Sandostatin LAR and Afinitor monotherapy may have the potential to control tumor growth in patients with advanced pancreatic neuroendocrine tumors. These results will be presented at the 11th World Congress on Gastrointestinal Cancer in Barcelona, Spain.
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Dell Tries to Make an EHR Splash
HealthDataManagement, 11/03/09
Novel agent for treatment of Parkinson's disease - Lu 02-750 - enters Lundbeck's development pipeline
Lundbeck, 11/02/09
Forest Laboratories, Inc. and Gedeon Richter Announce Positive Results from a Phase IIb Study of Cariprazine for the Treatment of Schizophrenia
Forest Laboratories, 10/29/09